Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication

Jeromie Ballreich; Charles Bennet; Thomas J Moore; G Caleb Alexander

doi:10.1001/jamaoncol.2021.4757

Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication

JAMA Oncol. 2021 Nov 1;7(11):1720-1721. doi: 10.1001/jamaoncol.2021.4757.

Authors

Jeromie Ballreich^{1

2}, Charles Bennet^{3

4}, Thomas J Moore^{2

5}, G Caleb Alexander^{1

2

6

7}

Affiliations

¹ Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
³ The University of South Carolina College of Pharmacy, Columbia.
⁴ The Center for Comparative Effectiveness, The City of Hope Comprehensive Cancer Center, Duarte, California.
⁵ Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC.
⁶ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁷ Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland.

Abstract

This cross-sectional study examines atezolizumab as a second-line treatment for malignant urothelial carcinoma, which received accelerated US Food and Drug Administration approval, although the manufacturer’s confirmatory trial did not identify benefits.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Health Expenditures*
Humans
Medicare*
United States

Substances

Antibodies, Monoclonal, Humanized
atezolizumab